ML-193
CAS No. 713121-80-3
ML-193 ( CID 1261822 )
Catalog No. M24723 CAS No. 713121-80-3
ML-193 is a potent and selective GPR55 antagonist( IC50 : 221 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 43 | In Stock |
|
5MG | 72 | In Stock |
|
10MG | 125 | In Stock |
|
25MG | 258 | In Stock |
|
50MG | 410 | In Stock |
|
100MG | 605 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameML-193
-
NoteResearch use only, not for human use.
-
Brief DescriptionML-193 is a potent and selective GPR55 antagonist( IC50 : 221 nM).
-
DescriptionML-193 is a potent and selective GPR55 antagonist( IC50 : 221 nM). It shows more than 27-fold selectivity for GPR55 over GPR35, CB1 and CB2, and can improve the motor and the sensorimotor deficits of Parkinson’s disease (PD) rats.
-
SynonymsCID 1261822
-
PathwayGPCR/G Protein
-
TargetCannabinoid Receptor
-
RecptorGPR55
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number713121-80-3
-
Formula Weight527.6
-
Molecular FormulaC28H25N5O4S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCc1c(NS(c(cc2)ccc2NC(c2cc(-c3ncccc3)nc3c(C)cc(C)cc23)=O)(=O)=O)onc1C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Fatemi I, et, al. The effect of intra-striatal administration of GPR55 agonist (LPI) and antagonist (ML193) on sensorimotor and motor functions in a Parkinson's disease rat model. Acta Neuropsychiatr. 2021 Feb;33(1):15-21.
molnova catalog
related products
-
AM-2201
A synthetic cannabinoid that acts as a potent, nonselective full agonist for the cannabinoid receptor with EC50 of 38 and 58 nM for CB1 and CB2, respectively.
-
AM-630
A potent and selective inverse agonist for the cannabinoid receptor CB2 with Ki of 32.1 nM, 165-fold selectivity over CB1.
-
AM1241
A potent, selective cannabinoid receptor CB2 agonist with Ki of 7.1 nM.